• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/9/21 6:17:42 AM ET
    $CGIX
    Medical Specialities
    Health Care
    Get the next $CGIX alert in real time by email
    SC 13G 1 ea134927-13gintra_cancer.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.   )*

     

    Cancer Genetics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    13739U203

    (CUSIP Number)

     

    February 1, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 8

     

     

    CUSIP No.     13739U203    

    1. Names of Reporting Persons.  
         
    Mitchell P. Kopin   
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a) ☐  
      (b) ☐  
    3. SEC Use Only  
    4.

    Citizenship or Place of Organization

     

    United States of America

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
     

     

    0

     
    6. Shared Voting Power   
     

    710,905

     
    7. Sole Dispositive Power
     
    0
     
    8. Shared Dispositive Power

    710,905
     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    710,905 (see Item 4)
     
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11. Percent of Class Represented by Amount in Row (9)

    9.99% (see Item 4)
     
    12. Type of Reporting Person (See Instructions)

    IN; HC
     

     

    Page 2 of 8

     

     

    CUSIP No.     13739U203    

    1. Names of Reporting Persons.  
         
    Daniel B. Asher  
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a) ☐  
      (b) ☐  
    3. SEC Use Only  
    4.

    Citizenship or Place of Organization

     

    United States of America

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
     

     

    0

     
    6. Shared Voting Power   
     
    710,905
     
    7. Sole Dispositive Power
     
    0
     
    8. Shared Dispositive Power

    710,905
     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    710,905 (see Item 4)
     
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11. Percent of Class Represented by Amount in Row (9)

    9.99% (see Item 4)
     
    12. Type of Reporting Person (See Instructions)

    IN; HC
     

     

    Page 3 of 8

     

     

    CUSIP No.     13739U203    

    1. Names of Reporting Persons.  
         
    Intracoastal Capital LLC  
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
         
      (a) ☐  
      (b) ☐  
    3. SEC Use Only  
    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5. Sole Voting Power
     

     

    0

     
    6. Shared Voting Power   
     
    710,905
     
    7. Sole Dispositive Power
     
    0
     
    8. Shared Dispositive Power

    710,905
     

    9. Aggregate Amount Beneficially Owned by Each Reporting Person

    710,905 (see Item 4)
     
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐
    11. Percent of Class Represented by Amount in Row (9)

    9.99% (see Item 4)
     
    12. Type of Reporting Person (See Instructions)

    OO
     

     

    Page 4 of 8

     

     

    Item 1.

     

    (a) Name of Issuer

     

    Cancer Genetics, Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    201 Route 17 North, 2nd Floor

    Rutherford, NJ 07070

     

    Item 2.

     

    (a) Name of Person Filing

    (b) Address of Principal Business Office or, if none, Residence

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    13739U203

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) and (b):

     

    Immediately following the consummation of the transaction contemplated by the Securities Purchase Agreement with the Issuer dated January 28, 2021 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on February 2, 2021) and as of the close of business on February 8, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 710,905 shares of Common Stock, which consisted of (i) 689,656 shares of Common Stock held by Intracoastal and (ii) 21,249 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (the “Intracoastal Warrant”), and all such shares of Common Stock in the aggregate represented beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 7,094,924 shares of Common Stock outstanding as of February 8, 2021 as reported to the Reporting Persons by the Issuer, plus (2) 21,249 shares of Common Stock issuable upon exercise of the Intracoastal Warrant. The foregoing excludes 668,407 shares of Common Stock issuable upon exercise of the Intracoastal Warrant because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,379,312 shares of Common Stock.

     

    Page 5 of 8

     

      

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote:     0    .

     

    (ii)Shared power to vote or to direct the vote:     710,905    .

     

    (iii)Sole power to dispose or to direct the disposition of     0   .

     

    (iv)Shared power to dispose or to direct the disposition of      710,905     .

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 6 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 9, 2021

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
         
      /s/ Daniel B. Asher
      Daniel B. Asher
         
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 7 of 8

     

     

    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 9, 2021

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
         
      /s/ Daniel B. Asher
      Daniel B. Asher
         
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 8 of 8

     

     

    Get the next $CGIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CGIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:48:08 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Marcus Boehm

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:46:47 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 4 filed by Joanna Horobin

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 9:32:36 PM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Genetics and StemoniX Announce Merger Closing

    Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of t

    3/31/21 6:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

    Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company RUTHERFORD, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ("StemoniX"). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Commo

    3/25/21 9:15:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    SEC Filings

    View All

    SEC Form 3 filed by Cancer Genetics, Inc.

    3 - Vyant Bio, Inc. (0001349929) (Issuer)

    4/1/21 7:03:48 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Cancer Genetics, Inc.

    10-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/31/21 6:01:06 AM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Cancer Genetics, Inc.

    8-K - CANCER GENETICS, INC (0001349929) (Filer)

    3/25/21 9:17:14 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

    RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment of Roland J. Carrillo, PhD as the Vice President of Business Development. Dr. Carrillo brings over a decade of experience with drug discovery and translational science with extensive knowledge of business development, marketing, and sales operations. His latest role was at Crown Bioscience, where he held positions as Senior Director for Sales Operations and Director of Business Development. He also led efforts in sales enablement, research service commercialization, and new business unit creation.

    3/18/21 8:30:00 AM ET
    $CGIX
    Medical Specialities
    Health Care

    $CGIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed

    SC 13D - CANCER GENETICS, INC (0001349929) (Subject)

    2/25/21 3:05:43 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:43:25 PM ET
    $CGIX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - CANCER GENETICS, INC (0001349929) (Subject)

    2/10/21 9:26:44 PM ET
    $CGIX
    Medical Specialities
    Health Care